Scientific Advisers

Dr. Yaping Shou

Date:2022-04-06 Views:84

    Dr. Yaping Shou is a seasoned physician-scientist and biopharmaceutical executive with extensive drug development experience in areas of clinical development and translational medicine, with a strong focus in oncology. During her 20-year biopharmaceutical career, she has held clinical development positions with increasing responsibilities in both big pharma (GlaxoSmithKline, Novartis, and Takeda) and small biotech (Trillium Therapeutics) companies. She most recently served as the chief medical officer of Trillium Therapeutics and the executive medical director with Takeda Pharmaceuticals prior to joining Trillium. Over the years, Dr. Shou has contributed to the development and regulatory approval of multiple oncology drugs including lapatinib, pazopanib, nilotinib, sonidegib, and ixazomib. She received her MD from Zhejiang University School of Medicine and her PhD in Cellular and Molecular Biology from Drexel University College of Medicine and the University of Pennsylvania. Her postdoctoral studies were conducted in the Genetics Branch at the National Cancer Institutes.

    As a female executive, Dr. Shou received leadership training at SAID Business School of University of Oxford and MIT Sloan School of Management during her tenure at Takeda. She also participated in a 12-month women leadership development program for high-potential women led by WOMAN Unlimited, Inc. Throughout her career, Dr. Shou has demonstrated scientific and business leadership skills in strategy development, program and portfolio management, partnership and external alliance, fundraising and investor relations, staffing and coaching, and budgets and operations.